{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T15:02:56Z","timestamp":1788793376292,"version":"build-2803163510"},"reference-count":106,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Gastroenterology"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.bpg.2017.04.009","type":"journal-article","created":{"date-parts":[[2017,5,5]],"date-time":"2017-05-05T01:47:03Z","timestamp":1493948823000},"page":"281-289","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["What is new on HBsAg and other diagnostic markers in HBV infection?"],"prefix":"10.1016","volume":"31","author":[{"given":"Christoph","family":"H\u00f6ner zu Siederdissen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Maasoumy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Cornberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bpg.2017.04.009_bib1","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","article-title":"Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013","volume":"386","author":"Schweitzer","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2017.04.009_bib2","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jhep.2006.05.013","article-title":"The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide","volume":"45","author":"Perz","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.bpg.2017.04.009_bib3","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.bpg.2017.04.009_bib4","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2017.04.009_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.bpg.2017.04.009_bib6","first-page":"554","article-title":"[Prognostic significance of quantitative HBsAg determination in acute hepatitis B. Partial report of a cooperative clinical study of the DFG-focus of \u201cvirus hepatitis\u201d]","volume":"83","author":"Gerlich","year":"1977","journal-title":"Verh Dtsch Ges Inn Med"},{"key":"10.1016\/j.bpg.2017.04.009_bib7","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jhep.2016.08.009","article-title":"The role of quantitative hepatitis B surface antigen revisited","volume":"66","author":"Cornberg","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.bpg.2017.04.009_bib8","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1128\/JVI.52.2.396-402.1984","article-title":"Large surface proteins of hepatitis B virus containing the pre-s sequence","volume":"52","author":"Heermann","year":"1984","journal-title":"J Virol"},{"key":"10.1016\/j.bpg.2017.04.009_bib9","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1053\/j.gastro.2014.04.030","article-title":"Strategies to inhibit entry of HBV and HDV into hepatocytes","volume":"147","author":"Urban","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2017.04.009_bib10","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3748\/wjg.v13.i1.65","article-title":"Hepatitis B virus morphogenesis","volume":"13","author":"Bruss","year":"2007","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.bpg.2017.04.009_bib11","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jhep.2010.01.014","article-title":"Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective","volume":"52","author":"Jaroszewicz","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.bpg.2017.04.009_bib12","doi-asserted-by":"crossref","first-page":"e43143","DOI":"10.1371\/journal.pone.0043143","article-title":"Hepatitis B surface antigen concentrations in patients with HIV\/HBV co-infection","volume":"7","author":"Jaroszewicz","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bpg.2017.04.009_bib13","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.cgh.2007.09.005","article-title":"Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response","volume":"5","author":"Chan","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2017.04.009_bib14","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/hep.23571","article-title":"Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers","volume":"51","author":"Thompson","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2017.04.009_bib15","first-page":"222A","article-title":"Reductions in cccDNA under NUC and ARC-520 therapy in chimpanzees with chronic hepatitis B virus infection implicate integrated DNA in maintaining circulating HBsAg","volume":"62","author":"Woodell","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2017.04.009_bib16","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jcv.2010.12.008","article-title":"Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum","volume":"50","author":"Wursthorn","year":"2011","journal-title":"J Clin Virol"},{"key":"10.1016\/j.bpg.2017.04.009_bib17","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jcv.2011.04.005","article-title":"A comparison of two assays for quantification of hepatitis B surface antigen in patients with chronic hepatitis B","volume":"51","author":"Sonneveld","year":"2011","journal-title":"J Clin Virol"},{"key":"10.1016\/j.bpg.2017.04.009_bib18","doi-asserted-by":"crossref","first-page":"141","DOI":"10.7754\/Clin.Lab.2014.140722","article-title":"Comparison between Elecsys HBsAg II and Architect assays for quantification of serum hepatitis B surface antigen in Chinese patients with chronic hepatitis B","volume":"61","author":"Liu","year":"2015","journal-title":"Clin Lab"},{"key":"10.1016\/j.bpg.2017.04.009_bib19","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1128\/CVI.05122-11","article-title":"Multicenter evaluation of the Elecsys hepatitis B surface antigen quantitative assay","volume":"18","author":"Zacher","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.bpg.2017.04.009_bib20","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jcv.2014.05.013","article-title":"Quantification of hepatitis B surface antigen with the novel DiaSorin LIAISON XL Murex HBsAg Quant: correlation with the ARCHITECT quantitative assays","volume":"60","author":"Burdino","year":"2014","journal-title":"J Clin Virol"},{"key":"10.1016\/j.bpg.2017.04.009_bib21","doi-asserted-by":"crossref","first-page":"S524","DOI":"10.1016\/S0168-8278(15)30766-2","article-title":"Evaluation of large, middle and small hepatitis B surface (HBS) proteins in HBeAg positive patients","volume":"62","author":"Rinker","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.bpg.2017.04.009_bib22","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1128\/JCM.00366-07","article-title":"Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection","volume":"45","author":"Wong","year":"2007","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.bpg.2017.04.009_bib23","doi-asserted-by":"crossref","first-page":"606.e1","DOI":"10.1016\/j.cmi.2015.02.010","article-title":"Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D","volume":"21","author":"Maasoumy","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.bpg.2017.04.009_bib24","doi-asserted-by":"crossref","first-page":"21713","DOI":"10.1074\/jbc.M501564200","article-title":"Hepatitis B virus DNA-negative dane particles lack core protein but contain a 22-kDa precore protein without C-terminal arginine-rich domain","volume":"280","author":"Kimura","year":"2005","journal-title":"J Biol Chem"},{"issue":"Suppl 1","key":"10.1016\/j.bpg.2017.04.009_bib25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000122592","article-title":"Hepatitis B core-related antigen assay is useful for monitoring the antiviral effects of nucleoside analogue therapy","volume":"51","author":"Tanaka","year":"2008","journal-title":"Intervirology"},{"key":"10.1016\/j.bpg.2017.04.009_bib26","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/1469-0691.12739","article-title":"Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B","volume":"20","author":"Seto","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.bpg.2017.04.009_bib27","article-title":"Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA","author":"Wong","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.bpg.2017.04.009_bib28","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/jmv.21339","article-title":"Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients","volume":"81","author":"Suzuki","year":"2009","journal-title":"J Med Virol"},{"key":"10.1016\/j.bpg.2017.04.009_bib29","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41598-017-00111-0","article-title":"Serum hepatitis B core-related antigen is a satisfactory surrogate marker of intrahepatic covalently closed circular DNA in chronic hepatitis B","volume":"7","author":"Chen","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.bpg.2017.04.009_bib30","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jhep.2016.05.029","article-title":"Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound","volume":"65","author":"Wang","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.bpg.2017.04.009_bib31","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/hep.27381","article-title":"Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors","volume":"61","author":"van B\u00f6mmel","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2017.04.009_bib32","doi-asserted-by":"crossref","first-page":"e43087","DOI":"10.1371\/journal.pone.0043087","article-title":"High hepatitis B surface antigen levels predict insignificant fibrosis in hepatitis B e antigen positive chronic hepatitis B","volume":"7","author":"Seto","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bpg.2017.04.009_bib33","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/hep.23803","article-title":"A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B","volume":"52","author":"Chan","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2017.04.009_bib34","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jhep.2010.01.007","article-title":"Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia","volume":"52","author":"Nguyen","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.bpg.2017.04.009_bib35","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/jmv.24657","article-title":"Serum HBV core-related antigen is a good predictor for spontaneous HBeAg seroconversion in chronic hepatitis B patients","volume":"89","author":"Song","year":"2017","journal-title":"J Med Virol"},{"key":"10.1016\/j.bpg.2017.04.009_bib36","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.jhep.2013.01.028","article-title":"Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-na\u00efve, e antigen-positive patients","volume":"58","author":"Martinot-Peignoux","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.bpg.2017.04.009_bib37","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1111\/jgh.12304","article-title":"Serum hepatitis B surface antigen quantification as a useful assessment for significant fibrosis in hepatitis B e antigen-positive hepatitis B virus carriers","volume":"28","author":"Xun","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2017.04.009_bib38","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.cgh.2014.12.017","article-title":"Serum levels of hepatitis B surface antigen predict severity of fibrosis in patients with E antigen-positive chronic hepatitis B","volume":"13","author":"Marcellin","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2017.04.009_bib39","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1365-2893.2007.00957.x","article-title":"Longitudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg-negative chronic hepatitis B virus infection","volume":"15","author":"Papatheodoridis","year":"2008","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.bpg.2017.04.009_bib40","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.bpg.2017.04.009_bib41","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1055\/s-0031-1273462","article-title":"[Prophylaxis, diagnosis and therapy of hepatitis B virus infection \u2013 the German guideline]","volume":"49","author":"Cornberg","year":"2011","journal-title":"Z Gastroenterol"},{"key":"10.1016\/j.bpg.2017.04.009_bib42","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1053\/j.gastro.2010.04.052","article-title":"Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers","volume":"139","author":"Brunetto","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2017.04.009_bib43","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jcv.2013.08.010","article-title":"Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA","volume":"58","author":"Martinot-Peignoux","year":"2013","journal-title":"J Clin Virol"},{"key":"10.1016\/j.bpg.2017.04.009_bib44","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/hep.28552","article-title":"Serum levels of hepatitis B surface antigen and DNA can predict inactive carriers with low risk of disease progression","volume":"64","author":"Liu","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2017.04.009_bib45","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.cgh.2016.01.019","article-title":"Repeated measurements of hepatitis B surface antigen identify carriers of inactive HBV during long-term follow-up","volume":"14","author":"Brouwer","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2017.04.009_bib46","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1002\/hep.22884","article-title":"Hepatitis B virus DNA levels and outcomes in chronic hepatitis B","volume":"49","author":"Chen","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2017.04.009_bib47","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/infdis\/jir283","article-title":"Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients","volume":"204","author":"Chan","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bpg.2017.04.009_bib48","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1053\/j.gastro.2011.04.046","article-title":"Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters","volume":"141","author":"Tseng","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2017.04.009_bib49","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.cgh.2011.08.029","article-title":"Decreasing levels of HBsAg predict HBsAg seroclearance in patients with inactive chronic hepatitis B virus infection","volume":"10","author":"Chen","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2017.04.009_bib50","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/hep.21345","article-title":"Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens","volume":"44","author":"Sugiyama","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2017.04.009_bib51","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.jhep.2013.07.017","article-title":"Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype","volume":"59","author":"Brunetto","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.bpg.2017.04.009_bib52","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/hep.25592","article-title":"Impact of hepatitis B virus (HBV) preS\/S genomic variability on HBV surface antigen and HBV DNA serum levels","volume":"56","author":"Pollicino","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2017.04.009_bib53","doi-asserted-by":"crossref","first-page":"E45","DOI":"10.1111\/hepr.12208","article-title":"Characteristics and prediction of hepatitis B e-antigen negative hepatitis following seroconversion in patients with chronic hepatitis B","volume":"44","author":"Morita","year":"2014","journal-title":"Hepatol Res"},{"key":"10.1016\/j.bpg.2017.04.009_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2017.03.003","article-title":"Serum Hepatitis B core-related antigen is more accurate than HBsAg to identify inactive carriers, regardless of HBV genotype","author":"Riveiro-Barciela","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.bpg.2017.04.009_bib55","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jhep.2016.03.013","article-title":"HBcrAg predicts hepatocellular carcinoma development: an analysis using time-dependent receiver operating characteristics","volume":"65","author":"Tada","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.bpg.2017.04.009_bib56","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/hep.21282","article-title":"Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B","volume":"44","author":"Wursthorn","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2017.04.009_bib57","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/liv.13046","article-title":"Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B","volume":"36","author":"Chuaypen","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.bpg.2017.04.009_bib58","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.jhep.2013.01.029","article-title":"Serum levels of interferon-gamma-inducible protein 10 and response to peginterferon therapy in HBeAg-positive chronic hepatitis B","volume":"58","author":"Sonneveld","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.bpg.2017.04.009_bib59","doi-asserted-by":"crossref","first-page":"895","DOI":"10.3851\/IMP2580","article-title":"Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-\u03b12a and adefovir","volume":"18","author":"Takkenberg","year":"2013","journal-title":"Antivir Ther"},{"key":"10.1016\/j.bpg.2017.04.009_bib60","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.antiviral.2016.05.002","article-title":"Intrahepatic IP-10 mRNA and plasma IP-10 levels as response marker for HBeAg-positive chronic hepatitis B patients treated with peginterferon and adefovir","volume":"131","author":"Willemse","year":"2016","journal-title":"Antiviral Res."},{"key":"10.1016\/j.bpg.2017.04.009_bib61","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/hep.25636","article-title":"Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B","volume":"56","author":"Sonneveld","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2017.04.009_bib62","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1053\/j.gastro.2009.08.061","article-title":"Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa","volume":"137","author":"Buster","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2017.04.009_bib63","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1111\/j.1365-2036.2010.04474.x","article-title":"Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B","volume":"32","author":"Chan","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2017.04.009_bib64","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/hep.26436","article-title":"Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels","volume":"58","author":"Sonneveld","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2017.04.009_bib65","doi-asserted-by":"crossref","first-page":"S333","DOI":"10.1016\/S0168-8278(09)60919-3","article-title":"On-treatment monitoring of HBsAg levels to predict response to peginterferon alfa-2a in patients with HBeAg-positive chronic hepatitis B","volume":"50","author":"Lau","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.bpg.2017.04.009_bib66","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/hep.23844","article-title":"Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline","volume":"52","author":"Sonneveld","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2017.04.009_bib67","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/hep.22744","article-title":"Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients","volume":"49","author":"Moucari","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2017.04.009_bib68","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/hep.23722","article-title":"Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels","volume":"52","author":"Rijckborst","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2017.04.009_bib69","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jhep.2011.12.007","article-title":"Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a","volume":"56","author":"Rijckborst","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.bpg.2017.04.009_bib70","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/jvh.12565","article-title":"Baseline HBsAg and HBcrAg titres allow peginterferon-based \u2018precision medicine\u2019 in HBeAg-negative chronic hepatitis B patients","volume":"23","author":"Martinot-Peignoux","year":"2016","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.bpg.2017.04.009_bib71","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/infdis\/jiv397","article-title":"Hepatitis B virus pregenomic RNA is present in virions in plasma and is associated with a response to pegylated interferon alfa-2a and nucleos(t)ide analogues","volume":"213","author":"Jansen","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bpg.2017.04.009_bib72","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/hep.23785","article-title":"Long-term entecavir therapy results in the reversal of fibrosis\/cirrhosis and continued histological improvement in patients with chronic hepatitis B","volume":"52","author":"Chang","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2017.04.009_bib73","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2017.04.009_bib74","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jhep.2014.08.045","article-title":"Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir","volume":"62","author":"Papatheodoridis","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.bpg.2017.04.009_bib75","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/hep.26180","article-title":"Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection","volume":"58","author":"Hosaka","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2017.04.009_bib76","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jhep.2012.11.039","article-title":"Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside\/nucleotide analogue therapy: Finite treatment duration unlikely","volume":"58","author":"Chevaliez","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.bpg.2017.04.009_bib77","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/infdis\/jir282","article-title":"Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss","volume":"204","author":"Zoutendijk","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bpg.2017.04.009_bib78","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jhep.2014.08.031","article-title":"Quantification of HBsAg in nucleos(t)ide-na\u00efve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study","volume":"62","author":"Zoulim","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.bpg.2017.04.009_bib79","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jhep.2013.06.007","article-title":"Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment","volume":"59","author":"Seto","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.bpg.2017.04.009_bib80","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1002\/hep.23905","article-title":"Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients","volume":"52","author":"Wursthorn","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2017.04.009_bib81","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1093\/jac\/dkw019","article-title":"\u03b1-Fetoprotein level-dependent early hepatitis B surface antigen decline during entecavir therapy in chronic hepatitis B with hepatitis flare","volume":"71","author":"Jeng","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bpg.2017.04.009_bib82","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3851\/IMP1866","article-title":"Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside\/nucleotide analogues","volume":"16","author":"Jaroszewicz","year":"2011","journal-title":"Antivir Ther"},{"key":"10.1016\/j.bpg.2017.04.009_bib83","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jhep.2013.08.023","article-title":"Changes of HBsAg and interferon-inducible protein 10 serum levels in naive HBeAg-negative chronic hepatitis B patients under 4-year entecavir therapy","volume":"60","author":"Papatheodoridis","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.bpg.2017.04.009_bib84","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/jvh.12434","article-title":"Serum HBsAg kinetics and usefulness of interferon-inducible protein 10 serum in HBeAg-negative chronic hepatitis B patients treated with tenofovir disoproxil fumarate","volume":"22","author":"Papatheodoridis","year":"2015","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.bpg.2017.04.009_bib85","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1053\/j.gastro.2010.03.059","article-title":"Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B","volume":"139","author":"Reijnders","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2017.04.009_bib86","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/hep.28438","article-title":"Discontinuation of oral antivirals in chronic hepatitis B: a systematic review","volume":"63","author":"Papatheodoridis","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2017.04.009_bib87","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jcv.2010.02.014","article-title":"On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients","volume":"48","author":"Cai","year":"2010","journal-title":"J Clin Virol"},{"key":"10.1016\/j.bpg.2017.04.009_bib88","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ijid.2015.10.019","article-title":"Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients","volume":"43","author":"Qiu","year":"2016","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.bpg.2017.04.009_bib89","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1053\/j.gastro.2012.05.039","article-title":"Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir","volume":"143","author":"Hadziyannis","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2017.04.009_bib90","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/apt.13272","article-title":"Systematic review: cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B","volume":"42","author":"Chang","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2017.04.009_bib91","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.cgh.2016.03.024","article-title":"Association between serum level of hepatitis B surface antigen at end of entecavir therapy and risk of relapse in E antigen-negative patients","volume":"14","author":"Hsu","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2017.04.009_bib92","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/ajg.2016.109","article-title":"Assessing the durability of entecavir-treated hepatitis B using quantitative HBsAg","volume":"111","author":"Wang","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.bpg.2017.04.009_bib93","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jhep.2014.04.029","article-title":"The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment","volume":"61","author":"Chen","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.bpg.2017.04.009_bib94","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/j.cgh.2015.06.002","article-title":"Association between level of hepatitis B surface antigen and relapse after entecavir therapy for chronic hepatitis B virus infection","volume":"13","author":"Chen","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2017.04.009_bib95","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.3851\/IMP1921","article-title":"Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients","volume":"16","author":"Chan","year":"2011","journal-title":"Antivir Ther"},{"key":"10.1016\/j.bpg.2017.04.009_bib96","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1007\/s00535-015-1153-1","article-title":"Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients","volume":"51","author":"Jung","year":"2016","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.bpg.2017.04.009_bib97","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00535-013-0800-7","article-title":"Serum HBV RNA as a possible marker of HBV replication in the liver during nucleot(s)ide analogue therapy","volume":"48","author":"Kurosaki","year":"2013","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.bpg.2017.04.009_bib98","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.gastro.2014.10.038","article-title":"American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Perrillo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2017.04.009_bib99","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/ajg.2016.436","article-title":"Association of hepatitis B core-related antigen with hepatitis B virus reactivation in occult viral carriers undergoing high-risk immunosuppressive therapy","volume":"111","author":"Seto","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.bpg.2017.04.009_bib100","doi-asserted-by":"crossref","DOI":"10.1002\/hep.29135","article-title":"Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals","author":"Belperio","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2017.04.009_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(17)30909-1","article-title":"Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: a systematic review and meta-analysis","author":"Chen","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2017.04.009_bib102","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/hep.20944","article-title":"Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus\/hepatitis C virus-coinfected patients","volume":"43","author":"Raimondo","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2017.04.009_bib103","doi-asserted-by":"crossref","first-page":"710.e1","DOI":"10.1016\/j.cmi.2015.03.003","article-title":"Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-gamma-induced protein 10 levels in HBV\/HCV-coinfected patients","volume":"21","author":"Wiegand","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.bpg.2017.04.009_bib104","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/hep.22951","article-title":"Hepatitis B and C virus coinfection: a novel model system reveals the absence of direct viral interference","volume":"50","author":"Bellecave","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2017.04.009_bib105","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1093\/infdis\/jiw457","article-title":"Direct-acting antiviral-induced hepatitis C virus clearance does not completely restore the altered cytokine and chemokine milieu in patients with chronic hepatitis C","volume":"214","author":"Hengst","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bpg.2017.04.009_bib106","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.3109\/00365520903329585","article-title":"Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin","volume":"44","author":"Potthoff","year":"2009","journal-title":"Scand J Gastroenterol"}],"container-title":["Best Practice & Research Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169181730032X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169181730032X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T23:39:52Z","timestamp":1602027592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152169181730032X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":106,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S152169181730032X"],"URL":"https:\/\/doi.org\/10.1016\/j.bpg.2017.04.009","relation":{},"ISSN":["1521-6918"],"issn-type":[{"value":"1521-6918","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What is new on HBsAg and other diagnostic markers in HBV infection?","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpg.2017.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}